ArticleThe journal of obstetrics and gynaecology research2026
Effects of Micronized Progesterone in Menopausal Hormone Replacement Therapy on Sleep.
Article in The journal of obstetrics and gynaecology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimIn Japan, only synthetic progestins were available for menopausal hormone therapy until 2021. Since then, micronized progesterone has become available. Micronized progesterone binds to gamma-aminobutyric acid type A receptors and exerts sedative and hypnotic effects. This study evaluated the effects of micronized progesterone on sleep in women receiving estrogen-progestogen therapy.
methodsThis retrospective study was approved by the institutional review board. Eligible participants were women who switched from synthetic progestins to micronized progesterone between December 2022 and September 2024. Women using sleep medications were excluded. Sleep quality was assessed using the Athens Insomnia Scale before switching, 3 months, and 1 year after initiating micronized progesterone. Progesterone was administered cyclically or continuously. In cyclic users, the Insomnia Severity Index was used to compare sleep during treatment and treatment-free phases.
resultsA total of 36 participants were included, of whom 22 completed a 1-year follow-up. At 3 months, sleep induction (p = 0.002) and awakenings during the night (p = 0.028) on the Athens Insomnia Scale improved, although the total score remained unchanged. At 1 year, no significant changes were observed. Among 11 participants with baseline scores ≤ 3, the total Athens Insomnia Scale scores significantly worsened at 3 months and 1 year. No significant differences in Insomnia Severity Index scores were observed between treatment and non-treatment periods.
conclusionsMicronized progesterone improved sleep induction and reduced awakenings during the night at 3 months; however, benefits diminished by 1 year. Sleep conditions worsened in women without preexisting sleep disorders. Regular monitoring is recommended during long-term micronized progesterone therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.